President's Page

Obesity and Acute Coronary Syndromes

STEFANOS FOUSSAS

Cardiology Department, Tzaneio State Hospital, Piraeus, Greece

I n modern times, obesity has become a "pandemic" of global and growing proportions. In the general population, obesity is associated with increased mortality.[1] Obese individuals have a higher incidence of cardiovascular risk factors, such as hypertension, dyslipidemia and diabetes mellitus. Therefore, this group of patients has higher morbidity and mortality associated with diseases of the cardiovascular system. Because weight reduction is associated with an improved cardiovascular risk profile, the guidelines for the primary prevention of cardiovascular disease recommend weight reduction in overweight and obese patients.[2] Despite the limited scientific data, these recommendations have also been expanded to the guidelines for coronary artery disease[3,4] and heart failure.[5]

The effects of obesity on the cardiovascular system are varied and include increased insulin resistance, elevated blood pressure, systemic inflammation and procoagulant state, dyslipidaemia, increased sympathetic activity, heart failure, endothelial dysfunction, coronary artery disease, atrial fibrillation, stroke, and systolic and diastolic dysfunction.[6] Therefore, recent guidelines for the primary prevention of coronary heart disease recommend a reduction in body weight in overweight and obese patients.[6]

In fact, epidemiological data suggest a protective role of obesity against some common diseases. It was first observed that obesity is a favorable prognostic factor in patients with end-stage renal failure.[6] Thus was created the concept of the "obesity paradox". In addition, the "obesity paradox" arose in diseases such as heart failure,[7] atrial fibrillation,[8] sudden cardiac death,[9] and coronary artery disease.[10]

The effect of the "obesity paradox" is also apparent in patients with acute coronary syndromes (ACS).

In particular, the MADIT II study found an inverse correlation between body mass index (BMI) and total mortality and sudden cardiac death in patients with systolic dysfunction after acute myocardial infarction (AMI).[7,8]

Moreover, a recent meta-analysis of several studies by Niedjela et al[8] found that both overweight and obese patients had lower mortality after AMI than patients with normal weight; similar results are seen in patients with severe obesity, thus suggesting the possible presence of the "obesity paradox" in coronary artery disease. In the same meta-analysis, overweight patients had 30% lower mortality after ACS compared to patients with a normal BMI; obese patients had 40% lower mortality, and even severely obese subjects (BMI>40 kg/m^2) had 30% lower mortality compared to patients with a normal BMI.

In a study by Herrmann et al,[9] after three years' monitoring, post-AMI patients who were overweight or obese had better outcomes than normal or underweight patients with regard to the overall death rate. The same patients showed no difference in rates of cardiac death according to BMI. We can conclude that the difference in overall mortality between overweight and normal-weight individuals is due more to other comorbidities apart from coronary disease. In the above study, after multivariate analysis, obesity as determined by BMI was not an independent predictor of mortality in patients with ST-elevation myocardial infarction (STEMI).

The SYNERGY trial, which included 9000 patients with non-ST-elevation ACS,[10] found that the annual mortality was greatest in underweight patients, improving with increasing BMI in overweight and obese patients, and levelling off in severely obese patients (BMI>40 kg/m^2), creating the characteristic J-curve of the "obesity paradox".

In addition, a study by Angeras et al confirmed the findings of the preceding meta-analysis that patients who are overweight or obese have better survival compared with lean patients, and that this difference increases as we move further in time from the ACS episode, while there is no evidence that excessively obese patients have lower mortality.[11]

In an analysis by Das et al that included more than 50,000 patients with STEMI, excessively obese patients, even though younger, with less extensive coronary artery disease, less impaired left ventricular systolic performance, and receiving the same quality of therapy, showed greater in-hospital mortality. Furthermore, patients with normal weight had a higher rate of major bleeding.[12]

The main mechanisms of increased mortality in class III obese individuals (BMI>40 kg/m^2) are increased blood volume, increased filling pressures, and increased activation of the sympathetic system. In addition, the proinflammatory and thrombotic state make up an important mechanism of increased mortality in extremely obese patients. Additionally, the increased cardiac mass predisposes to arrhythmias and sudden death, increasing mortality in these patients. At the same time, respiratory complications, such as aspiration pneumonia, sleep apnea, pulmonary thromboembolism, and other hypoventilation syndromes, as well as the prolonged immobility, the difficulty of placing lines, and weight limitations in diagnostic and therapeutic examinations such as angiography, act as catalysts to increase mortality in patients after ACS, according to the study by Das et al.[12] In addition, a study by Wienbergen et al found that obese patients manifest coronary artery disease at a younger age.[13]

Regarding the therapeutic approach to patients with ACS, we see that overweight or obese patients receive a higher rate of treatment with aspirin, angiotensin-converting enzyme inhibitors, beta-blockers, and statins, and are more likely to stop smoking, according to a meta-analysis by Steinberg et al.[14] The same meta-analysis also confirmed that underweight patients were less likely to undergo catheterisation, angioplasty, or coronary artery bypass grafting.

Summarizing the main reasons for the phenomenon of the "obesity paradox" in patients with acute coronary syndrome, overweight or obese patients are younger, have less extensive angiographic coronary artery disease, and usually adopt a more aggressive approach to risk factor modification, while obesity may protect against malignant ventricular arrhythmias during and after AMI. reducing the risk of sudden death.[7]

Possible pathophysiological mechanisms behind the "obesity paradox" include the action of adipose tissue, as the largest endocrine organ, producing hormones (leptin, adiponectin, resistin) with cardioprotective effects after OEM.[15] These effects are probably associated with less arrhythmogenesis and hence reduce the risk of sudden death in patients with ACS.[16] Unlike underweight patients, low levels of adiponectin are found in the obese during the first 4 weeks after AMI; therefore, obese patients have better survival.

The guidelines suggest maintaining an ideal body weight with a BMI of 25 kg/m^2 and a reduction in body weight if BMI>30 kg/m^2 or when waist circumference is >102 cm and >88 cm for women, as weight reduction improves several risk factors related to obesity. Nevertheless, it has not yet been documented that a decrease in body weight *per se* reduces mortality in patients after STEMI.[17] Moreover, the reduction in body weight achieved is usually poor, with weight reduction in obese patients post AMI of only 0.5% and corresponding weight reduction in severely obese patients of 3.5% after one year.[18]

In conclusion, overweight and obese patients appear to have a lower risk of death after the occurrence of an ACS; this is known as the "obesity paradox". Young age, angiography at an earlier stage, and more aggressive treatment of ACS seems to be the aetiology of the "obesity paradox". The data are based mainly on meta-analyses and especially retrospective studies; therefore, prospective randomized studies will be required to further evaluate the effect of obesity in patients with ACS.

References

1. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003; 289: 187-193.
2. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. New Engl J Med. 1999; 341: 427-434.
3. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007; 28: 1598-1660.
4. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004; 110: 2952-2967.
5. Malcom J, Arnold O, Howlett JG, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart fail-

ure—2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol. 2008; 24: 21-40.

6. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012; 19: 403-488.

7. Choy B, Hansen E, Moss AJ, McNitt S, Zareba W, Goldenberg I; Multicenter Automatic Defibrillator Implantation Trial-II Investigators. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction. Am J Cardiol. 2010; 105: 581-586.

8. Niedziela J, Hudzik B, Niedziela N, et al. The obesity paradox in acute coronary syndrome: a meta-analysis. Eur J Epidemiol. 2014; 29: 801-812.

9. Herrmann J, Gersh BJ, Goldfinger JZ, et al. Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol. 2014; 114: 9-16.

10. Mahaffey KW, Tonev ST, Spinler SA, et al. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010; 139: 123-133.

11. Angerås O, Albertsson P, Karason K, et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J. 2013; 34: 345-353.

12. Das SR, Alexander KP, Chen AY, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2011; 58: 2642-2650.

13. Wienbergen H, Gitt AK, Juenger C, et al; MITRA PLUS study group. Impact of the body mass index on occurrence and outcome of acute ST-elevation myocardial infarction. Clin Res Cardiol. 2008; 97: 83-88.

14. Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GC. Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. Am J Cardiol. 2007; 100: 1331-1335.

15. Smith CC, Dixon RA, Wynne AM, et al. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol. 2010; 299: H1265-1270.

16. Tao L, Gao E, Jiao X, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007; 115: 1408-1416.

17. Steg PG, James SK, Atar D, et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33: 2569-2619.

18. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 1341-1352.